STAT3突变对大颗粒淋巴细胞白血病总生存的影响:205例单中心经验
该单中心研究分析205例大颗粒淋巴细胞白血病(LGLL)患者的临床与生物学特征,发现STAT3突变见于28.3%患者,并与中性粒细胞减少、贫血及治疗需求相关。多因素分析显示STAT3突变状态与Hb<90 g/L独立关联于总生存期缩短,提示STAT3突变可作为潜在治疗靶点。
要点
- STAT3突变见于28.3%的LGLL患者,与ANC<500/mm³、Hb<90 g/L及治疗需求相关。
- 多因素分析中STAT3突变状态与Hb<90 g/L独立关联于总生存期缩短。
- STAT3突变可能作为LGLL的潜在治疗靶点。
核心结论
- STAT3突变状态与Hb<90 g/L独立关联于LGLL患者总生存期缩短,提示STAT3突变应被视为潜在治疗靶点。
研究设计与样本
- 单中心回顾性分析205例LGLL患者的临床与生物学特征,以识别影响预后的标志物。
主要发现
- 中性粒细胞减少(ANC<1500/mm³)为主要特征,占38%,严重中性粒细胞减少(ANC<500/mm³)见于20.5%患者。
- STAT3突变见于28.3%患者,与ANC<500/mm³(p<0.0001)、Hb<90 g/L(p=0.0079)及治疗需求(p<0.0001)相关。
- STAT5b突变在15/152例无症状患者中检出。
- 年龄校正单因素分析显示ANC<500/mm³(p=0.013)、Hb<90 g/L(p<0.0001)、治疗需求(p=0.001)及STAT3突变状态(p=0.011)与总生存期缩短相关。
- 多因素分析显示STAT3突变状态(p=0.0089)与Hb<90 g/L(p=0.0011)独立关联于总生存期缩短。
临床怎么用
- 对LGLL患者应检测STAT3突变状态,结合Hb水平进行预后分层。
- STAT3突变合并Hb<90 g/L提示总生存期可能缩短,需加强病情监测与治疗评估。
局限性
- 单中心回顾性研究,结论需多中心前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The aim of this study is to analyze clinical and biological features of a large cohort of LGLL patients to identify prognostic markers affecting patients' outcome. In 205 LGLL patients, neutropenia (ANC < 1500/mm3) was the main feature (38%), with severe neutropenia (ANC < 500/mm3) being present in 20.5% of patients. STAT3 mutations were detected in 28.3% patients and were associated with ANC < 500/mm3 (p < 0.0001), Hb < 90 g/L (p = 0.0079) and treatment requirement (p < 0.0001) while STAT5b mutations were found in 15/152 asymptomatic patients. By age-adjusted univariate analysis, ANC < 500/mm3 (p = 0.013), Hb < 90 g/L (p < 0.0001), treatment requirement (p = 0.001) and STAT3 mutated status (p = 0.011) were associated to reduced overall survival (OS). By multivariate analysis, STAT3 mutated status (p = 0.0089) and Hb < 90 g/L (p = 0.0011) were independently associated to reduced OS. In conclusion, we identified clinical and biological features associated to reduced OS in LGLL and we demonstrated the adverse impact of STAT3 mutations in patients' survival, suggesting that this biological feature should be regarded as a potential target of therapy.
引用
- Barilà G, Teramo A, Calabretto G, et al. Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia. 2019. PMID: 31740810. doi:10.1038/s41375-019-0644-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。